PF-07275315 compared with placebo in adults with moderate to severe COPD
Tests PF-07275315 given as shots in adults with moderate to severe COPD.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Bangor, Birmingham, Boerne, Carrollton, Chappaqua, Columbia, Cypress, Dallas, Dearborn, Dothan, DuBois, East Point, Fall River, Flint, Flushing, Franklin, Gaffney, Greenacres City, Hammond, Henderson, Hendersonville, Houston, Kansas City, Kissimmee, La Palma, Loxahatchee Groves, Merrillville, Miami, Mobile, Mount Kisco, Newport Beach, North Dartmouth, Northridge, Ocala, Philadelphia, Phoenix, Phoenixville, Rapid City, Rincon, Rock Hill, San Diego, Sherman, Southfield, Spartanburg, St Louis, St. Petersburg, Tampa, Toledo, Troy, Tulsa, Winston-Salem, Winter Park, and Zachary, United StatesSee the 64 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 80 years old?
Source: NCT07363694, who can take part
Where in United States
- Paul A. Shapero, MD, PABangor, United StatesNot yet recruiting
- University of Alabama at Birmingham - Lung Health CenterBirmingham, United StatesTaking people
- South Texas Medical Research Institute, Inc., DBA TTS ResearchBoerne, United StatesTaking people
- Ten20 Clinical ResearchCarrollton, United StatesTaking people
- Northwell Health Physician Partners at ChappaquaChappaqua, United StatesNot yet recruiting
- Bogan Sleep Consultants, LLCColumbia, United StatesTaking people
- Horizon Clinical Research GroupCypress, United StatesTaking people
- Alina Clinical Trials, LLC.Dallas, United StatesTaking people
- Baylor Scott & White Advanced Lung Disease SpecialistsDallas, United StatesTaking people
- Baylor University Medical CenterDallas, United StatesTaking people
- Baylor University Medical Center (Research Office)Dallas, United StatesTaking people
- Revival Research Institute, LLCDearborn, United StatesTaking people
- SEC Clinical ResearchDothan, United StatesTaking people
- Clinical Research Associates of Central Pa, LLCDuBois, United StatesTaking people
- Cpcc-Research LlcEast Point, United StatesTaking people
- Exordia Medical Research IncFall River, United StatesTaking people
- AA Medical Research CenterFlint, United StatesTaking people
- New York Presbyterian QueensFlushing, United StatesTaking people
- Clinical Trials Center of Middle Tennessee, LLCFranklin, United StatesTaking people
- Velocity Clinical Research, GaffneyGaffney, United StatesTaking people
- Finlay Medical ResearchGreenacres City, United StatesTaking people
- ASHA Clinical Research-Munster, LLCHammond, United StatesTaking people
- Henderson Clinical TrialsHenderson, United StatesTaking people
- Premier Research Center, LLCHendersonville, United StatesTaking people
- Greater Heights Memorial Pulmonary and SleepHouston, United StatesTaking people
- Houston Pulmonary Sleep and Allergy AssociatesHouston, United StatesTaking people
- University of Kansas Medical CenterKansas City, United StatesTaking people
- Clinical Research Specialists, LLCKissimmee, United StatesTaking people
- IMAX Clinical TrialsLa Palma, United StatesTaking people
- Advanced Pulmonary Research InstituteLoxahatchee Groves, United StatesTaking people
- Methodist Hospital SouthlakeMerrillville, United StatesTaking people
- Reed Medical ResearchMiami, United StatesTaking people
- Pulmonary Associates of Mobile, P.C.Mobile, United StatesTaking people
- Northern Westchester HospitalMount Kisco, United StatesNot yet recruiting
- NewportNativeMD, Inc.Newport Beach, United StatesTaking people
- Infinity Medical ResearchNorth Dartmouth, United StatesTaking people
- California Medical Research AssociatesNorthridge, United StatesTaking people
- HCA Florida Ocala Imaging CenterOcala, United StatesTaking people
- Ocala Lung and Critical Care AssociatesOcala, United StatesTaking people
- Renstar Medical ResearchOcala, United StatesTaking people
- Temple University HospitalPhiladelphia, United StatesNot yet recruiting
- Pulmonary Associates, PAPhoenix, United StatesTaking people
- Temple Health OaksPhoenixville, United StatesNot yet recruiting
- Health ConceptsRapid City, United StatesTaking people
- Centricity Research Rincon PulmonologyRincon, United StatesTaking people
- Clinical Research of Rock HillRock Hill, United StatesTaking people
- Institute of HealthCare Assessment d/b/a Apex Clinical ResearchSan Diego, United StatesTaking people
- Sherman Clinical ResearchSherman, United StatesTaking people
- Revive Research Institute, IncSouthfield, United StatesTaking people
- Velocity Clinical Research, SpartanburgSpartanburg, United StatesTaking people
- Barnes-Jewish HospitalSt Louis, United StatesTaking people
- Barnes-Jewish Hospital Investigational Drug ServiceSt Louis, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
- Washington University School-Cardiovascular Imaging and Clinical Research Core LaboratorySt Louis, United StatesTaking people
- Coastal Medical Research Institute, LLCSt. Petersburg, United StatesTaking people
- Coastal Pulmonary and Critical Care, P.L.C.St. Petersburg, United StatesTaking people
- Clinical Research Trials of Florida, Inc.Tampa, United StatesTaking people
- Toledo Institute of Clinical Research Inc.Toledo, United StatesTaking people
- Oakland Medical ResearchTroy, United StatesTaking people
- Layrek Clinical ResearchTulsa, United StatesTaking people
- Salem Chest SpecialistsWinston-Salem, United StatesTaking people
- Southeastern Research CenterWinston-Salem, United StatesTaking people
- Clinical Site Partners, LLC dba Flourish ResearchWinter Park, United StatesTaking people
- Southern Clinical Research, LLCZachary, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07363694EU 2024-518587-12-00
- Record updated
- 22 October 2026
- Original description
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.Read full original descriptionShow less
AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.
This study is seeking participants who:
* Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months * Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months
All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.
PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.
Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic.
Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.
Inclusion: Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition); Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [<] 70 percent (%) and post-bronchodilator FEV1 % predicted <70%, but greater than equal to 30%); Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months; Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.
Exclusion: Requirement for continuous chronic treatment with oxygen at >4.0 liters / minute by nasal cannula or equivalent; Significant pulmonary disease other than COPD; Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale; Hypoxemia with a resting SpO2 <88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).